Quantification of titanium dioxide nanoparticles in human urine by single-particle ICP-MS.
Samantha SalouDominic LarivièreCiprian-Mihai CirtiuNormand FleuryPublished in: Analytical and bioanalytical chemistry (2020)
The increasing use of titanium dioxide nanoparticles in daily use consumer products such as cosmetics, personal care products, food additives, and even medicine has led to growing concerns regarding human safety. It would be ideal to track exposure to this emerging nanopollutant, for example through bioassays, however, so far nanoparticle assessment in biological matrices such as urine remains challenging. The lack of data is mainly due to the limitations of the current metrology, but also to the low expected concentration in human samples. In this study, a quantification method for titanium dioxide nanoparticles in urine has been developed and validated following the ISO/CEI 17025:2017 guidelines. The detection limit for titanium dioxide nanoparticle mass concentration by single-particle inductively coupled plasma mass spectrometry (SP-ICP-MS) was 0.05 ng mL-1. The particle size limit was determined using three different approaches, with the highest calculated limit value approaching 50 nm. Repeatability and reproducibility of 14% and 18% respectively were achieved for particle mass concentration, and 6% for both parameters for particle size determination. Method trueness and recovery were 98% and 84%, respectively.
Keyphrases
- mass spectrometry
- endothelial cells
- induced pluripotent stem cells
- multiple sclerosis
- pluripotent stem cells
- healthcare
- palliative care
- big data
- quality improvement
- social media
- photodynamic therapy
- capillary electrophoresis
- clinical practice
- health information
- pain management
- health insurance
- solid phase extraction
- climate change
- molecularly imprinted